Friday, 16 October 2026European Markets

DISRUPTIVE CAP SHA Stock Over 26% Down In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of DISRUPTIVE CAP SHA (AEX-Index: DCACS.AS) fell by a staggering 26% in 10 sessions from €10 to €7.40 at 19:09 EST on Thursday, after five sequential sessions in a row of losses. AEX-Index is jumping 1.48% to €727.06, following the last session's downward trend.

About DISRUPTIVE CAP SHA

Disruptive Capital Acquisition Company Limited does not have significant operations. It intends to complete a merger, amalgamation, share exchange, asset and/or liability acquisition, share purchase, reorganization, or related business combination with a target business or entity operating in the financial services sector. The company was incorporated in 2021 and is based in Saint Peter Port, Guernsey.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DISRUPTIVE CAP SHA's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for DISRUPTIVE CAP SHA is 143 which is 80.8% below its average volume of 745.

Volatility

DISRUPTIVE CAP SHA's last week, last month's, and last quarter's current intraday variation average was a negative 11.11%, a negative 8.26%, and a positive 3.73%.

DISRUPTIVE CAP SHA's highest amplitude of average volatility was 11.11% (last week), 8.26% (last month), and 3.73% (last quarter).

More news about DISRUPTIVE CAP SHA (DCACS.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com